Nirsevimab Reduced Infant Antibiotic Use
A study found infants who received the RSV preventive saw fewer antibiotic prescriptions for common respiratory illnesses.
Updated on Sept. 18, 2026 in Asthma
Live Poll
Do you believe preventative infant treatments are an effective way to lower future antibiotic use?
Between 2023 and 2025, infants who received nirsevimab for RSV prevention were prescribed significantly fewer antibiotics for common respiratory infections. The findings suggest that preventing upstream viral illness can lower overall antibiotic use among infants.
Why it matters
Reducing antibiotic prescriptions is vital for preventing the development of antibiotic-resistant bacteria. This study demonstrates that effective viral prevention strategies can decrease the need for secondary antibiotic treatments in infants.
In a study of 15,341 infants tracked over two respiratory seasons, those receiving nirsevimab had a 40.3% reduction in bronchiolitis-related antibiotic prescriptions and a 69.4% reduction in RSV hospitalizations compared to those who did not receive the preventive.
The players
Children's Hospital of Philadelphia
A pediatric academic medical center that served as the primary clinical site for the research study.
The details
Nirsevimab works by providing passive immunity to protect infants from Respiratory Syncytial Virus (RSV). By preventing the initial viral infection, the medication lowers the likelihood that an infant will develop secondary bacterial complications that typically require antibiotic treatment. This intervention specifically targets the upstream source of the infection, thereby curbing the downstream reliance on antibiotics for conditions like acute otitis media or other viral respiratory infections.
Timeline
The nirsevimab vaccine debuted in 2023.
The study spanned two respiratory virus seasons from 2023 to 2025.
Health Landscape
This research provides clinical evidence for the broader public health goal of reducing unnecessary antibiotic use in pediatric populations. It builds on the introduction of nirsevimab as a standard preventive intervention for RSV.
Parents and caregivers should discuss the availability of RSV prevention options with their pediatrician to understand how these measures might protect their infant from severe illness. Understanding the link between viral prevention and antibiotic use is an important part of informed pediatric care.
The takeaway
Preventing RSV with nirsevimab can significantly decrease the need for antibiotics in infants by stopping viral infections before they progress. Caregivers should talk to their pediatrician about the best respiratory virus prevention plan for their child.
Further reading
Learn more about managing respiratory health and pediatric care in the Asthma section.
Source note: This article includes information reported by Healio.
Live Poll
Do you believe preventative infant treatments are an effective way to lower future antibiotic use?
